A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity (ATTAIN-NOW)
EU CTIS ID: 2026-526175-35-00
What this study is testing
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have an increased waist-to-height ratio of ≥0.5
- Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia)
- Have at least one unsuccessful attempt to reduce body weight based on diet and exercise
- Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds
You likely can't join if
- Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- Do not have a stable body weight within 90 days before screening
- Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold)
- Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening
- Have a prior or planned surgical treatment or procedure for obesity
- Have hypertension or history of hypertension
See the full eligibility criteria
- Have an increased waist-to-height ratio of ≥0.5
- Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia)
- Have at least one unsuccessful attempt to reduce body weight based on diet and exercise
- Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds
- Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- Do not have a stable body weight within 90 days before screening
- Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold)
- Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening
- Have a prior or planned surgical treatment or procedure for obesity
- Have hypertension or history of hypertension
- Have dyslipidemia or history of dyslipidemia
The study team makes the final eligibility decision.
Where it's taking place
- Czechia
- Germany
- Spain
- Japan
- Taiwan
- United States
- India
- Argentina
- Mexico
- China
- Korea, Republic of
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Czechia; Germany; Spain; Japan; Taiwan; United States and 5 more locations. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.